CRISPR Therapeutics AGCRSP

Market cap

$4.7B

P/E ratio

	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Cash and cash equivalents	316	240	-	944	1,169	923	212	390	298
Marketable securities	-	-	-	-	522	1,456	1,603	1,304	1,606
Accounts receivable	3	3	0	0	0	0	-	200	25
Prepaid expenses and other current assets	2	6	10	44	26	38	38	14	8
Total current assets	320	248	466	988	1,717	2,418	1,853	1,908	1,937
Property and equipment, net	21	19	19	31	42	138	164	152	134
Marketable Securities, Noncurrent	-	-	-	-	-	-	53	2	-
Intangible assets, net	0	0	0	0	0	0	0	0	-
Restricted cash	-	-	-	5	17	17	12	12	12
Operating lease assets	-	-	-	42	51	174	157	154	143
Other non-current assets	0	1	1	1	1	5	5	2	16
Total assets	345	271	489	1,067	1,828	2,752	2,243	2,230	2,242
Accounts payable	5	2	5	6	9	15	27	38	15
Accrued expenses	16	11	21	30	54	91	78	45	41
Deferred revenue, current	-	-	-	1	2	1	-	4	4
Taxes Payable, Current	0	0	0	1	10	1	0	0	0
Operating lease liabilities	-	-	-	8	11	12	16	16	17
Other current liabilities	0	0	0	11	7	0	0	5	10
Total current liabilities	22	15	28	57	94	120	121	109	88
Deferred revenue, non-current	-	-	58	12	12	12	12	14	12
Operating Lease, Liability, Noncurrent	-	-	-	44	50	213	228	223	206
Other non-current liabilities	0	0	0	14	8	7	6	1	3
Total liabilities	112	84	97	127	164	352	368	347	310
Common Stock, Value, Issued	1	1	2	2	2	2	2	2	3
Treasury shares, at cost, 170,316 shares at December 31, 2024 and at December 31, 2023	-	-	0	0	0	0	0	0	0
Additional paid-in capital	289	312	682	1,162	2,236	2,598	2,735	2,878	3,294
Accumulated deficit	-57	-125	-292	-225	-574	-196	-846	-1,000	-1,366
Accumulated other comprehensive income	-0	0	-0	0	-0	-5	-16	2	2
Total shareholders’ equity	233	188	392	939	1,664	2,399	1,875	1,883	1,932
Total liabilities and shareholders’ equity	345	271	489	1,067	1,828	2,752	2,243	2,230	2,242